You are here

Our science / Clinical Trials / Find a Trial / NCT01405118

Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

Back to Search Print Save as PDF Bookmark Trial

NCT01405118

Last updated on August 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bruxelles, , B-1070 Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult healthy male and/or female (of non child bearing potential) subjects.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with clinically significant systemic and laboratory abnormalities.

- Subjects with clinically significant infections within the past 3 months.

- Women of child-bearing potential.

NCT01405118
Pfizer
Completed
Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Arthritis, Rheumatoid, High Dose
Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT01414257
All Genders
17+
Years
Kitakyushu-shi, Fukuoka-ken
Rheumatoid Arthritis
Korean Post-marketing Surveillance for Xeljanz
NCT02984020
All Genders
19+
Years
Multiple Sites
Juvenile Idiopathic Arthritis
Efficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
All Genders
2+
Years
Multiple Sites
Knee Osteoarthritis, Hip Osteoarthritis
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
NCT02697773
All Genders
18+
Years
Multiple Sites
Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers
A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers
This study will evaluate the potential effect of CP 690,550 on the pharmacokinetics of metformin, a probe drug for organic cationic transport.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Rheumatoid Arthritis
Drug: Metformin/CP-690,550
Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
Experimental: Metformin/CP-690,550
Intervention: Drug: Metformin/CP-690,550
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult healthy male and/or female (of non child bearing potential) subjects.

Exclusion Criteria:

  • Subjects with clinically significant systemic and laboratory abnormalities.
  • Subjects with clinically significant infections within the past 3 months.
  • Women of child-bearing potential.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT01405118
A3921143
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now